Kempfert et al. [6] compared early SAVI-1 results with those of the FRANCE-2 and SENTINEL registries using the CoreValve (Medtronic Inc., Minneapolis, MN, USA) and SAPIEN/SAPIEN XT prosthesis. Even though they included 75% transfemoral cases, early mortality was comparable, the leakage rate extremely promising, and the pacemaker rate within the range of the SAPIEN system and superior to the CoreValve system. Furthermore, SAVI-1 and -2 outcomes compare well to those of a recent review of transapical second-generation transcatheter heart valves [12], a recently published report of the JUPITER registry using the JenaValve (JenaValve Technology GmbH, Munich, Germany) [13], and the transapical cohort of the GARY registry [14]. Thirty-day mortality in our series was 6.8% compared to 8.9%, 11.1% and 7.7% (in-hospital mortality), and pacemaker were implanted in 10.2% compared to 12.1%, 14.4% and 11.3%, respectively. Bailout situation (valve-in-valve implantations and conversion to open heart) occurred in 2.2% of our series, compared to 5.0% in the JUPITER study and 2.0% (valve-in-valve procedures only) in the GARY registry.